Bayer AG has entered into a takeover agreement with Cara Care
December 2024 — Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Cara Care is a digital digestive health solution from Germany that combines both mental and nutritional therapy options. Its MDR Class I-approved treatment for irritable bowel syndrome (IBS) is fully reimbursed by all German statutory health insurance (SHI) and DiGA-certified providers. DiGA refers to digital health applications that are approved for use in Germany and are eligible for reimbursement under the country’s SHI system. The company is a pioneer in the field and is driving growth in an underserved sector. Cara Care has built a product pipeline that addresses not only IBS but also heartburn, dyspepsia and inflammatory bowel disease (IBD).
Bayer AG is a global enterprise with core competencies in the life sciences fields of healthcare and agriculture. Founded in 1863 and headquartered in Leverkusen, Germany, Bayer is known for its innovation-driven approach to improving quality of life. The company operates across three main divisions: pharmaceuticals, consumer health and crop science, delivering products and solutions that address some of the world’s most pressing challenges, particularly in health and food security.
Our role in the transaction
Oaklins’ team in Germany provided comprehensive advisory services to the insolvency administrator and Cara Care in this transaction.
Talk to the deal team
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreNextalia has acquired a majority stake in Witapp
Nextalia SGR S.p.A. has acquired a majority stake in Witapp S.r.l., an Italian company specializing in software development for the digitization of healthcare infrastructure. The acquisition strengthens Nextalia’s track record in technology companies serving the public sector and supports its strategy of investing in businesses operating at the intersection of healthcare digitization and the modernization of public services.
Learn moreLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn more